Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. is one of the world's largest independent biotechnology companies, developing biologic therapies that address serious illnesses across oncology, cardiovascular disease, inflammation, and other therapeutic areas. The company's news flow reflects its position as a major pharmaceutical innovator, with developments spanning regulatory approvals, clinical trial results, financial performance, and strategic initiatives.
Following Amgen's news provides insight into the biotechnology sector's evolution and the regulatory pathway for bringing complex biologic therapies to market. The company regularly announces FDA decisions on new therapies and expanded indications for existing products, offering real-time visibility into which treatments are gaining regulatory approval and market access. Clinical trial data releases reveal the company's research progress across its development pipeline, while earnings reports detail financial performance across geographic markets and product portfolios.
Amgen's announcements frequently include updates on cardiovascular therapies targeting cholesterol management, oncology supportive care products, and treatments for inflammatory conditions and bone health disorders. The company also announces manufacturing expansions that signal investment in biomanufacturing capacity and strategic moves including acquisitions, partnerships, and licensing agreements that shape its therapeutic portfolio. Investor presentations and analyst conferences provide management's perspective on business priorities and market dynamics affecting the broader biologics sector.
This news feed aggregates material disclosures, regulatory milestones, and corporate developments specific to Amgen, providing a centralized resource for tracking one of biotechnology's pioneering companies as it navigates an increasingly competitive landscape shaped by biosimilar competition, pricing pressures, and evolving therapeutic approaches.
Amgen will present virtually at the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. The presentation will be conducted by Rob Lenz, M.D., Ph.D., and Peter H. Griffith, focusing on Amgen's business developments. The webcast will be accessible to the public through Amgen's website, with an archive available for 90 days post-event. Amgen is a leading biotechnology firm, committed to improving health outcomes through innovative human therapeutics, and is recognized as one of the top sustainable companies globally.
Amgen (NASDAQ: AMGN) will present crucial data from its oncology portfolio at the AACR Annual Meeting in New Orleans, April 8-13, 2022. A highlight will be the late-breaking oral presentation of long-term outcomes from the CodeBreaK 100 trial for LUMAKRAS® (sotorasib), a KRASG12C inhibitor for non-small cell lung cancer (NSCLC), on April 10. Additional data will cover preclinical results from AMG 794 and TNB-928b. Over 40 countries have approved LUMAKRAS, which has been administered to more than 4,000 patients globally.
Amgen (NASDAQ:AMGN) has commenced construction on a new biomanufacturing facility in Holly Springs, North Carolina, aimed to be operational by 2025. This facility will enhance Amgen's capability to meet the rising demand for its medicines targeting severe health issues like cancer and heart disease, creating over 350 high-quality jobs.
The plant will utilize advanced technologies to maximize production efficiency and adhere to strict environmental standards, supporting Amgen's goal of carbon neutrality by 2027.
Amgen will virtually present at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 11:10 a.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will lead the presentation. Interested parties can access the conference via a live webcast on Amgen's website, which will also archive the event for 90 days. Amgen, a leading biotechnology company, focuses on innovative human therapeutics and has been recognized for its workplace and sustainability efforts.
Amgen's Board of Directors has declared a $1.94 per share dividend for the second quarter of 2022. This dividend will be paid on June 8, 2022, to stockholders of record by the close of business on May 17, 2022. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics aimed at serious illnesses. The company is recognized for its commitment to sustainability and workplace excellence, being listed among the 25 World's Best Workplaces™ and 100 most sustainable companies globally.
Amgen (NASDAQ:AMGN) announced positive outcomes from a pooled analysis of NAVIGATOR Phase 3 and PATHWAY Phase 2b trials, showcasing TEZSPIRE™ (tezepelumab-ekko) effectively reduced asthma exacerbation rates across various biomarker subgroups. The analysis revealed reductions of 71% in patients with high eosinophil counts, 48% in those with lower counts, and significant effectiveness across seasons, indicating TEZSPIRE's ability to manage severe asthma irrespective of inflammatory drivers. Approved in the U.S., TEZSPIRE is under review in the EU, Japan, and other markets.
Amgen (NASDAQ: AMGN) announced promising results from the CodeBreaK 100 trial for LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated advanced pancreatic cancer. The trial revealed a 21% objective response rate (ORR) and an 84% disease control rate (DCR) across 38 heavily pre-treated patients. The median progression-free survival was 4 months, and overall survival reached nearly 7 months. No new safety signals emerged, with treatment-related adverse events occurring in 42% of patients. Amgen plans to expand the trial to enroll more patients with various tumor types.
Amgen (NASDAQ:AMGN) outlines its growth strategy through 2030, focusing on expanding its global patient reach with innovative medicines. CEO Robert A. Bradway emphasizes a diverse portfolio in significant therapeutic categories, backed by a robust pipeline and strong balance sheet. CFO Peter Griffith projects mid-single digit revenue CAGR and approximately 50% operating margins. Key growth drivers include the launch of biosimilars and the anticipated success of therapies like Otezla and Repatha. Amgen aims to return an average of 60% of net income to shareholders, alongside significant capital investments.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
